JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 16, 2006; DOI: 10.1124/jpet.106.108480


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Erratum
Right arrow All Versions of this Article:
jpet.106.108480v1
319/2/887    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bianchini, R.
Right arrow Articles by Riccardi, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bianchini, R.
Right arrow Articles by Riccardi, C.
Right arrowPubmed/NCBI databases
*GEO DataSet*GEO Profiles
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DEXAMETHASONE


Received for publication May 30, 2006.
Revised July 12, 2006.
Accepted for publication August 15, 2006.

Modulation of pro- and anti-apoptotic molecules in double positive (CD4+CD8+) thymocytes following dexamethasone treatment

Rodolfo Bianchini 1, Giuseppe Nocentini 1, Ludovic Tibor Krausz 1, Katia Fettucciari 1, Stefano Coaccioli 1, Simona Ronchetti 1, Carlo Riccardi 1*

1 University of Perugia

* Address correspondence to: E-mail: riccardi{at}unipg.it

Abstract

Glucocorticoids play a role in regulation of T lymphocytes homeostasis and development. In particular, glucocorticoid treatment induces massive apoptosis of CD4+CD8+ double positive (DP) thymocytes. This effect is due to many mechanisms, mainly driven by modulation of gene transcription. To find out which genes are modulated, we analyzed DP thymocytes treated for 3 hours with dexamethasone (a synthetic glucocorticoid), by global gene expression profiling. Results indicate modulation of 163 genes, also confirmed by either RNAse protection assay or Real Time PCR. In particular, dexamethasone caused down-regulation of genes promoting DP thymocyte survival (e.g. Notch1, Suppressor of cytokine signaling 1-Socs1 and Inhibitor of DNA binding 3-Id3) or modulation of genes activating cell death through the ceramide pathway (UDP-glucose ceramide glucosyltransferase-Ugcg, sphingosine 1-phosphate phosphatase-Sgpp1, dihydroceramide desaturase, isoform 1-Degs1 and G-protein-coupled receptor 65-Gpr65) or through the mithocondrial machinery. Among the latter, there are Bcl-2 family members (Bim, Bfl-1, Bcl-xL and Bcl-x{beta}), genes involved in the control of redox status (thioredoxin reductase, thioredoxin reductase inhibitor-Txnip and NADP+-dependent isocitrate dehydrogenase-Idh2) and genes belonging to Tis11 family which are involved in mRNA stability. Our study suggests that dexamethasone treatment of DP thymocytes modulates several genes belonging to apoptosis-related systems that can contribute to their apoptosis.


Key words: apoptosis, double positive thymocytes, gene profiling, gene trascription regulation, glucocorticoid hormones, microarray


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
S. Cuzzocrea, S. Bruscoli, E. Mazzon, C. Crisafulli, V. Donato, R. Di Paola, E. Velardi, E. Esposito, G. Nocentini, and C. Riccardi
Peroxisome Proliferator-Activated Receptor-{alpha} Contributes to the Anti-Inflammatory Activity of Glucocorticoids
Mol. Pharmacol., February 1, 2008; 73(2): 323 - 337.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.